On July 17, Pharmaron (03759.HK) declined 5.05% in regular trading, trading at HKD 23.4/share, with turnover of HKD 113 million. The decline extends the pullback that began the previous session, as the broader CRO sector experiences profit-taking following a sharp rally driven by experimental monkey price surges.

On the news front, Norges Bank disclosed on July 16 that it reduced its Pharmaron holdings by 1.3353 million shares on July 14 at approximately HKD 22.86 per share, lowering its stake to 6.93%. Meanwhile, the CRO sector showed significant divergence after the experimental monkey-fueled rally, with fund managers noting that while monkey scarcity ignited sentiment, the sustainability of the rebound depends on whether mid-year earnings can support elevated valuations. The CRO index had previously surged 21.72% from June 8 to July 10.

Within the Life Sciences Tools and Services sector, all major peers are declining today: Wuxi AppTec down 5.19%, Wuxi Biologics down 4.58%, Insilico down 10.57%, Wuxi XDC down 7.76%, and Joinn down 9.99%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)